Michael Solomon Net Worth

Michael Solomon biography

Dr. Michael Edward Solomon Ph.D. serves as Independent Director of the Company. Dr. Solomon has more than 20 years of experience in the biotechnology industry and has spent the last 14 years focused on creating and operating early stage companies. Dr. Solomon has served as chief executive officer of Ribometrix, Inc., a privately held therapeutics company focused on targeting RNA with small molecules, since October 2017. Dr. Solomon served as a venture partner at SV Health Investors from December 2016 until December 2018. Previously, Dr. Solomon served as chief operating officer at Decibel Therapeutics, Inc., a biotechnology company focused on hearing disorders, from 2015 until 2016. Dr. Solomon served as chief operating officer of Ember Therapeutics, Inc., a publicly traded pharmaceutical company, from 2012 until 2015, and as chief business officer of Link Medicine Corporation, a privately held biopharmaceutical company, from 2009 until 2012. Dr. Solomon was a founder and vice president of discovery at Epizyme Therapeutics, Inc., a clinical stage biopharmaceutical company, and vice president of discovery at Hypnion, Inc., a sleep disorder company that was sold to Lilly in 2007. Dr. Solomon has served as a member of the board of directors of ArTara since May 2018 and currently serves on the board of directors of Ribometrix, Inc., a privately held platform therapeutics company. Dr. Solomon earned his B.S. in chemistry from the University of Massachusetts, Amherst and his Ph.D. in organic chemistry from the University of Wisconsin. Dr. Solomon's industry experience in creating and operating early stage companies provide him with the qualifications to serve on the Company's board of directors.

What is the salary of Michael Solomon?

As the Independent Director of Protara Therapeutics Inc, the total compensation of Michael Solomon at Protara Therapeutics Inc is $82,878. There are 7 executives at Protara Therapeutics Inc getting paid more, with Jesse Shefferman having the highest compensation of $1,255,836.

How old is Michael Solomon?

Michael Solomon is 50, he's been the Independent Director of Protara Therapeutics Inc since 2020. There are 5 older and 8 younger executives at Protara Therapeutics Inc. The oldest executive at Protara Therapeutics Inc is Roger Garceau, 66, who is the Independent Director.

What's Michael Solomon's mailing address?

Michael's mailing address filed with the SEC is C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK, NY, 10010.

Insiders trading at Protara Therapeutics Inc

Over the last 5 years, insiders at Protara Therapeutics Inc have traded over $3,287,540 worth of Protara Therapeutics Inc stock and bought 250,034 units worth $1,947,929 . The most active insiders traders include Management Inc. Opaleye, Richard S Levy e Gregory Sargen. On average, Protara Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $34,731. The most recent stock trade was executed by Management Inc. Opaleye on 9 September 2024, trading 61,992 units of TARA stock currently worth $114,065.

What does Protara Therapeutics Inc do?

protara therapeutics, inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. the company's lead program is tara-002, an investigational cell therapy for the treatment of lymphatic malformations. it also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. the company was formerly known as artara therapeutics, inc. and changed its name to protara therapeutics, inc. in may 2020. protara therapeutics, inc. is based in new york, new york.

Protara Therapeutics Inc executives and stock owners

Protara Therapeutics Inc executives and other stock owners filed with the SEC include:

• Jesse Shefferman,
  Co-Founder, CEO, Pres & Director
• Blaine T. Davis,
  CFO, Principal Financial & Accounting Officer and Sec.
• Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D.,
  Chief Scientific Operations Officer
• Jesse Shefferman,
  President, Chief Executive Officer, Director
• Jacqueline Zummo,
  Senior Vice President - Research Operations
• Luke Beshar,
  Chairman of the Board
• Roger Garceau,
  Independent Director
• Michael Solomon,
  Independent Director
• Gregory Sargen,
  Independent Director
• Richard Levy,
  Independent Director
• Barry Flannelly,
  Director
• Blaine Davis,
  Chief Financial Officer
• Kristine Rosse,
  Sr. VP & Chief People Officer
• Justine O'Malley,
  Sr. VP of Investor Relations & Corp. Affairs
• Hannah Fry,
  Principal Accounting Officer & Controller
• Mary J. Grendell,
  Corp. Sec.
• Dr. Jathin Bandari M.D.,
  Interim Chief Medical Officer, VP & Head of Clinical Devel.
• Dr. Martin Sebastian Olivo M.D.,
  Chief Medical Officer
• Management Inc. Opaleye,
  10% owner
• Scott Braunstein,
  Director
• L.P. Opaleye,,
  10% owner
• Randall Marshall,
  
• Hannah Fry,
  VP, Controller
• Julio Casoy,
  Chief Medical Officer
• Martin Sebastian Olivo,
  Chief Medical Officer
• Jathin Bandari,
  Chief Medical Officer
• Patrick Fabbio,
  Chief Financial Officer
• Cynthia Smith,
  
• Jane Huang,